NCT00593736已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals With Delayed Sleep Phase Syndrome (DSPS)
Takeda0 个研究点目标入组 132 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 132
- 主要终点
- Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7)
研究概览
简要总结
The purpose of this study is to evaluate the ability of ramelteon, once daily (QD), to advance the timing of sleep in individuals with delayed sleep phase syndrome.
详细描述
Delayed sleep phase syndrome is the most common circadian disorder in adolescents and most adults with the condition report onset of symptoms during childhood or adolescence. Delayed Sleep Phase Syndrome involves a chronic mismatch between the usual daily schedule required by the individual's environment and his or her circadian sleep wake pattern. Individuals suffering from delayed Sleep Phase Syndrome experience great difficulty when attempting to fall asleep before 1-2 am, if not later, as well as rising at acceptable hours of the morning despite having completely normal sleep architecture and sleep duration. Delayed Sleep Phase Syndrome is a sleep disorder that results from a dysregulation of the circadian sleep-wake rhythm. Delayed Sleep Phase Syndrome is often the cause of severe insomnia and is associated with excessive daytime sleepiness, major depressive disorder and severe disruption of education, work and social functioning. Its major symptom is extreme difficulty initiating sleep at a conventional hour and waking on time in the morning for school or work.
Ramelteon is a selective melatonin type 1 (MT1) and type 2 (MT2) receptor agonist. The purpose of this study is to evaluate the ability of ramelteon to advance the timing of sleep in individuals with delayed sleep phase syndrome. The effect of ramelteon will be analyzed based on collection of information from a post-sleep questionnaire completed by participants, and data collected by polysomnography in a sleep clinic setting. Total participation time involved in this study will be approximately 7 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females of childbearing potential who is sexually active must agree to use adequate contraception from screening throughout the duration of the study.
- •Must have a diagnosis of Delayed Sleep Phase Syndrome according to International Classification of Sleep Disorders criteria for at least 3 months.
- •Based on sleep history, subject's habitual sleep time is more than 3 hours later than the desired sleep time.
- •Must have had self reported insomnia which is defined per the sleep history as his or her sleep latency of at least 45 minutes when attempting to sleep at desired sleep time required by his or her work or school schedule.
- •The subjective sleep latency via Post sleep questionnaire during outpatient screening period must be greater than or equal to 45 minutes during every working night or school night provided the subject went to bed at their desired sleep time.
- •During single blind placebo run-in Polysomnography screening nights, subject is instructed to go to bed at their desired bed time and must demonstrate difficulty in falling asleep based on the following criteria:
- •During Polysomnography screening nights when the subject goes to bed at their desired sleep time or
- •The average of total wake time
- •Is in good health as determined by a medical and psychiatric history, physical examination, Electrocardiogram, and serum chemistry and hematology.
- •Is able to complete self-rating scales via interactive voice response system, and has a touch tone phone.
- •Is willing to comply with study procedures and restrictions with fixed sleep time and wake time during the study and to attend regularly scheduled clinic visits as specified in this protocol.
- •Has a body mass index is between 18 and 34 kg/m2, inclusive.
- •Has a negative urine test result for selected substances of abuse (including alcohol).
- •Has a negative test result for hepatitis B surface antigen and hepatitis C virus antibody or history of human immunodeficiency virus.
- •Has not used pharmacological sleep assistance for more than 4 times/week during the 3 months prior to Initial Screening.
- •Must have discontinued use of all pharmacological sleep aids beginning 1 week prior to Visit 2 and for the duration of the trial.
排除标准
- •Has a known hypersensitivity to ramelteon or related compounds, including melatonin and melatonin-related compounds or 5-hydroxytryptophan.
- •Has participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives prior to the first dose of study medication, whichever is longer.
- •Has flown across greater than 3 time zones within the past 3 months prior to administration of study medication.
- •Has sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the administration of study medication.
- •Has participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of study medication.
- •Has a history of alcohol abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, or regularly consumes more than 14 alcoholic drinks per week or consumes any alcoholic drinks within 24 hours of Screening Visit.
- •Has a history of drug abuse within the past 12 months.
- •Has a current, clinically significant neurological (including cognitive), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, as determined by the investigator.
- •Has a probable current diagnosis of another circadian rhythm disorder or a sleep disorder other than Delayed Sleep Phase Syndrome that is the primary cause of insomnia.
- •Had an apnea hypopnea index greater than 10 on the first night of Polysomnography Screening.
- •Has periodic limb movements during sleep with arousal index greater than 10 as seen on the first night of Polysomnography screening only.
- •Has a positive urine drug screen or breathalyzer test.
- •Has ever had a history of seizures; sleep apnea, restless leg syndrome, chronic obstructive pulmonary disease, fibromyalgia, or a positive test result for the aforementioned ailments on the screening Polysomnography, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
- •Has a history of psychiatric disorder (including anxiety or depression) within the past 12 months.
- •Smokes more than 3 cigarettes per day or uses tobacco products during nightly awakenings.
- •Routinely consumes caffeine including coffee, tea and/or other caffeine-containing beverages or food averaging more than 600 mg of caffeine per day.
- •Has used any central nervous system drug or other medications, including those used to treat psychiatric disorders, known to affect sleep/wake function within 1 week whichever is longer prior to the administration of single blind study drug.
- •Used melatonin, or other drugs/supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug) whichever is longer prior to the first dose of single blind medication.
- •Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- •Anxiolytics
- •Hypnotics
- •Antidepressants
- •Anticonvulsants
- •Sedating H1 antihistamines
- •Systemic steroids
- •Respiratory stimulants
- •Decongestants
- •Antipsychotics
- •Muscle relaxants
- •Over-the-counter and prescription diet aids
- •Narcotic analgesics
- •Beta Blockers
- •St. John's wort
- •Kava kava
- •Ginkgo biloba
- •Modafinil
- •Melatonin and all other drugs or supplements known to affect sleep/wake function will be prohibited within 1 week of the first dose of study medication and during the entire study.
- •Has any clinically important abnormal finding as determined by a medical history, physical examination, Electrocardiogram, or clinical laboratory tests as determined by the investigator.
- •Has a positive hepatitis panel including anti- Hepatitis A Virus, hepatitis B surface antigen or anti- hepatitis C virus.
- •Has any additional condition(s) that in the investigator's opinion would:
- •Affect sleep/wake function
- •Prohibit the subject from completing the study, or
- •Not be in the best interest of the subject.
- •Exhibits a placebo response during single-blinded placebo run in period.
- •Individuals with a habitual sleep time later than 4:00 am should not be included in the study.
研究组 & 干预措施
Ramelteon 1 mg QD
Experimental
干预措施: Ramelteon (Drug)
Ramelteon 4 mg QD
Experimental
干预措施: Ramelteon (Drug)
Ramelteon 8 mg QD
Experimental
干预措施: Ramelteon (Drug)
Placebo QD
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7)
时间窗: Nights 6-7
The elapsed time from the beginning of the polysomnography recording to the onset of the first 10 minutes of continuous sleep (ie, total number of epochs before the first 20 consecutive non-wake epochs divided by 2).
次要结局
- Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 13-14)(Nights 13-14)
- Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)(Nights 6-7)
- Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)(Nights 13-14)
- Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 6-7)(Nights 6-7)
- Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 13-14)(Nights 13-14)
- Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 6-7)(Nights 6-7)
- Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 13-14)(Nights 13-14)
- Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 6-7)(Nights 6-7)
- Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 13-14)(Nights 13-14)
- Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 6-7)(Nights 6-7)
- Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 13-14)(Nights 13-14)
- Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)(Nights 6-7)
- Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)(Nights 13-14)
- Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)(Nights 6-7)
- Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)(Nights 13-14)
- Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)(Nights 6-7)
- Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)(Nights 13-14)
- Total Sleep Time Measured by Actigraphy (Nights 6-7)(Nights 6-7)
- Total Sleep Time Measured by Actigraphy (Nights 13-14)(Nights 13-14)
- Sleep Efficiency Measured by Actigraphy (Nights 6-7)(Nights 6-7)
- Sleep Efficiency Measured by Actigraphy (Nights 13-14)(Nights 13-14)
- Wake Time During Sleep Interval Measured by Actigraphy (Nights 6-7)(Nights 6-7)
- Wake Time During Sleep Interval Measured by Actigraphy (Nights 13-14)(Nights 13-14)
- Wake Bouts Measured by Actigraphy (Nights 6-7)(Nights 6-7)
- Wake Bouts Measured by Actigraphy (Nights 13-14)(Nights 13-14)
- Sleep Latency Measured by Actigraphy (Nights 6-7)(Nights 6-7)
- Sleep Latency Measured by Actigraphy (Nights 13-14)(Nights 13-14)
- Sleep Time Measured by Actigraphy (Nights 6-7)(Nights 6-7)
- Sleep Time Measured by Actigraphy (Nights 13-14)(Nights 13-14)
- Wake Time Measured by Actigraphy (Nights 6-7)(Nights 6-7)
- Wake Time Measured by Actigraphy (Nights 13-14)(Nights 13-14)
- Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Sleep Quality Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Sleep Quality Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Sleep Time Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Sleep Time Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Getting up in the Morning Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Getting up in the Morning Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Ability to Concentrate in the Morning Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Ability to Concentrate in the Morning Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Subjective Level of Alertness Measured by a Post-sleep Questionnaire (Nights 6-7)(Nights 6-7)
- Subjective Level of Alertness Measured by a Post-sleep Questionnaire (Nights 13-14)(Nights 13-14)
- Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Digit Symbol Substitution Test(Day 15)
- Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Memory Recall Test--Immediate(Day 15)
- Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Memory Recall Test--Delayed(Day 15)
- Visual Analogue Scale for Mood(Day 15)
- Visual Analogue Scale for Feelings(Day 15)
- The Time of Dim Light Melatonin Secretion Onset(Day 15)
- The Time of Dim Light Melatonin Secretion Offset(Day 15)
- The Total Duration of Secretion of Melatonin(Day 15)
- The Area Under the Concentration-time Curve of Melatonin From 0 to 24 Hours(Day 15)
- Average Cmax (Maximum Observed Plasma Concentration) Calculated as the Average of Three Highest Cmax Observations Within the Sampling Period.(Day 15)
研究者
相似试验
已完成
2 期
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's DiseaseChronic InsomniaNCT00325728Takeda74
终止
3 期
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I DisorderAcute Depressive EpisodeNCT01467700Takeda490
已完成
4 期
Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic InsomniaChronic InsomniaNCT00492232Takeda135
已完成
2 期
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic InsomniaSleep Initiation and Maintenance DisordersNCT00755495Takeda472
已完成
4 期
Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult VolunteersCircadian DysregulationNCT00492011Takeda110